The Alzheimer's Forward Study

Currently Recruiting

26 Jul 2026

Up to $9,530

Melbourne, Australia

This clinical study is investigating a potential new treatment for Alzheimer’s disease. Alzheimer’s disease is the most common cause of dementia worldwide and affects memory, thinking, and the ability to carry out everyday activities.

Over time, an abnormal protein builds up develop in the brain, which damage nerve cells and lead to worsening symptoms. Alzheimer’s disease places a growing burden on individuals, families, and healthcare systems.

While some medicines are currently approved that can help slow the progression of the disease, there is still a strong need for further research into new and improved treatments.

The study medicine is a laboratory‑made antibody designed to attach to a protein linked to Alzheimer’s disease. It is designed to enter the brain more easily, which may allow it to work at lower doses and reduce some brain‑related side effects.

Apply now Speak with us 1300 171 351

Join our clinical trial

This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. It is not known whether the study drug may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur.

Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions.

Why participate?

  • Participation in a monitored clinical environment
  • Study visits scheduled
  • Support from a professional medical team
  • Reimbursement for your time and commitment

Study schedule

 

Intake 1 In-clinic stay:
26 July 2026 – 6 August 2026		 Follow-up visits:
11 August – 20 October 2026
6 visits during this period
Intake 2 In-clinic stay:
2 August 2026 – 13 August 2026		 Follow-up visits:
18 August – 27 October 2026
6 visits during this period
Intake 3 In-clinic stay:
3 August 2026 – 14 August 2026		 Follow-up visits:
19 August – 28 October 2026
6 visits during this period
Intake 4 In-clinic stay:
31 August 2026 – 11 September 2026		 Follow-up visits:
16 September – 25 November 2026
6 visits during this period

Study dates are subject to change. Our team will confirm details with you during the screening process.

Trial details

Additional eligibility

  • Males weighing at least 50 kg
  • Females weighing at least 40 kg

Study duration

  • 2 screening visits
  • 11 nights inpatient stay
  • 6 outpatient visits

Study medication

Administered via a IV infusion.

Ethics

An independent ethics committee has approved this clinical trial.

Are you a match?

Age

18 - 54 years old

Remuneration

Up to $9,530 *with screening reimbursement.
Full details outlined in consent form.

Gender

Male or Female

BMI

BMI 18 - 32 kg/m2

Commitment

11 nights, 6 clinic visits

Medical condition

Not taking any medications

Register your interest

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg






















Step 2 of 3
Medical History

We regularly have studies that allow participants who are (social) smokers.

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Preferences

While longer studies generally have a higher reimbursement, there are also studies with multiple short stays that have high reimbursements.
Referral Information



Consent to Information Use and Future Contact